The filing confirms a severe liquidity risk: the company has ~$22M cash but faces a potential ~$52M cash settlement obligation on the Series A Preferred Stock starting December 11, 2026. The stockholder vote on conversion is critical; failure to approve could force a dilutive or distressed financing. Monitor the reconvened 2026 Annual Meeting for the outcome of the stockholder vote on the Series A Preferred Stock conversion and the Nasdaq listing application.
Price Chart
Executive Summary
Adial Pharmaceuticals filed Amendment No. 1 to its Form 10-Q for the quarter ended June 30, 2026, primarily to respond to SEC staff comments and to update disclosures regarding the Azora Therapeutics acquisition, the related PIPE financing, and the Series A Preferred Stock cash settlement risk. The amendment also updates the status of the company's Nasdaq listing and reports a material weakness in internal control over financial reporting related to the complex transaction accounting. The filing confirms a net loss of $54.0 million for the six months ended June 30, 2026, including a $46.2 million acquired in-process R&D charge, and reiterates substantial doubt about the company's ability to continue as a going concern if the Series A Preferred Stock cash settlement obligations are triggered.
Key Facts
- Net loss of $54.0 million for the six months ended June 30, 2026, including a $46.2 million acquired in-process R&D charge from the Azora acquisition.
- Cash and cash equivalents of $28.7 million as of June 30, 2026; cash reserves of approximately $22.0 million as of September 30, 2026.
- Series A Preferred Stock cash settlement risk: if triggered, settling all shares would cost approximately $51.9 million based on the $4.01 closing price on September 30, 2026, far exceeding current cash.
- Stockholders' equity was negative ($38.4 million) as of June 30, 2026, leading to a Nasdaq deficiency notice on August 18, 2026.
- A material weakness in internal control over financial reporting was identified related to the accounting for the Merger, Financing, and Azora Note Exchange.
- Milestone warrant rights liability of $23.8 million as of June 30, 2026; subsequent amendments in September 2026 reclassified these rights as equity.
- The company has incurred losses each year since inception and expects to continue incurring losses.
- The company's focus has shifted to AT177, a colon-targeted AhR agonist for ulcerative colitis, which is still in IND-enabling studies.
Financial Impact
Net loss of $54.0 million for H1 2026; cash burn of $8.0 million from operations; potential cash settlement liability of ~$51.9 million for Series A Preferred Stock; negative stockholders' equity of $38.4 million.
Risk Factors
- Going concern risk if Series A Preferred Stock cash settlement is triggered, as cash is insufficient to cover the ~$51.9 million obligation.
- Nasdaq delisting risk due to negative stockholders' equity; the company submitted a compliance plan on October 2, 2026.
- Material weakness in internal controls could lead to future reporting errors or delays.
- Dilution risk from the conversion of Series A Preferred Stock (12.9M shares), pre-funded warrants (11.8M shares), and milestone warrants (up to 23.6M shares) upon stockholder approval.
- Clinical development risk: AT177 has not yet entered human trials; IND submission is planned for H1 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-Q/A Filing (Primary) | 0001213900-26-111121 |
| Document: ea030921601ex31-4.htm | 0001213900-26-111121 |
| Document: ea030921601ex31-3.htm | 0001213900-26-111121 |
| Document: ea030921601ex32-4.htm | 0001213900-26-111121 |
| Document: ea030921601ex32-3.htm | 0001213900-26-111121 |
| Document: 0001213900-26-111121-index-headers.html | 0001213900-26-111121 |
| Document: 0001213900-26-111121-index.html | 0001213900-26-111121 |
| Document: 0001213900-26-111121.txt | 0001213900-26-111121 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.92 (+4.62%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.92 (+4.62%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.92 (−8.29%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.92 (−8.29%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.92 (−5.08%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.92 (−10.91%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.92 (−10.91%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.92 (−24.76%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.92 (−24.76%) |
Aug 17, 2026 10w ago | 8-K | $4.99 | awaiting T+60 | — | $3.92 (−21.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers